Compare Stocks: BNR, MDXG, DBVT, and STTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.49 +1.9%	$12.26	$6.79 ▼ $41.72	$159.88M	1.29	46,343 shs	7,695 shs
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$600.48M	-1.04	474,307 shs	324,040 shs
MDXG MiMedx Group	$4.67 +1.1%	$4.51	$3.03 ▼ $7.97	$673.41M	1.18	1.18 million shs	391,115 shs
STTK Shattuck Labs	$5.97 +5.5%	$6.80	$1.70 ▼ $8.33	$568.06M	1.09	1.66 million shs	1.05 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+1.91%	-4.68%	+29.19%	+37.08%	+74.04%
DBVT DBV Technologies	+2.62%	-7.11%	-27.08%	-40.57%	-38.29%
MDXG MiMedx Group	+1.08%	+1.74%	-0.21%	+13.63%	-34.23%
STTK Shattuck Labs	+5.48%	-11.29%	-5.69%	-10.09%	+149.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.49 +1.9%	$12.26	$6.79 ▼ $41.72	$159.88M	1.29	46,343 shs	7,695 shs
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$600.48M	-1.04	474,307 shs	324,040 shs
MDXG MiMedx Group	$4.67 +1.1%	$4.51	$3.03 ▼ $7.97	$673.41M	1.18	1.18 million shs	391,115 shs
STTK Shattuck Labs	$5.97 +5.5%	$6.80	$1.70 ▼ $8.33	$568.06M	1.09	1.66 million shs	1.05 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+1.91%	-4.68%	+29.19%	+37.08%	+74.04%
DBVT DBV Technologies	+2.62%	-7.11%	-27.08%	-40.57%	-38.29%
MDXG MiMedx Group	+1.08%	+1.74%	-0.21%	+13.63%	-34.23%
STTK Shattuck Labs	+5.48%	-11.29%	-5.69%	-10.09%	+149.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	394.90% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	83.54% Upside
STTK Shattuck Labs	3.00	Buy	$13.33	123.34% Upside

Current Analyst Ratings Breakdown

Latest BNR, MDXG, DBVT, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	STTK Shattuck Labs	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$11.00 ➝ $14.00
10/2/2026	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $19.00
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/15/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	2.11	N/A	N/A	$7.28 per share	2.13
DBVT DBV Technologies	$5.64M	109.26	N/A	N/A	$4.20 per share	2.33
MDXG MiMedx Group	$418.63M	1.63	$0.56 per share	8.34	$1.73 per share	2.70
STTK Shattuck Labs	$1M	599.15	N/A	N/A	$1.30 per share	4.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	116.78	27.47	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest BNR, MDXG, DBVT, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	MDXG MiMedx Group	$0.0067	N/A	N/A	N/A	$69.65 million	N/A
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
DBVT DBV Technologies	N/A	3.72	3.72
MDXG MiMedx Group	0.07	5.33	4.79
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
DBVT DBV Technologies	71.74%
MDXG MiMedx Group	79.15%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
DBVT DBV Technologies	1.06%
MDXG MiMedx Group	2.50%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
MDXG MiMedx Group	808	145.76 million	142.12 million	Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable

BNR, MDXG, DBVT, and STTK Headlines

Recent News About These Companies

Shattuck Labs (STTK) Receives a Buy from Leerink Partners

October 5, 2026 | theglobeandmail.com

Shattuck Labs (NASDAQ:STTK) Stock Price Down 5.3% - What's Next?

October 5, 2026 | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) Stock

October 4, 2026 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

October 2, 2026 | marketbeat.com

Financial Contrast: MDxHealth (NASDAQ:MDXH) and Shattuck Labs (NASDAQ:STTK)

October 2, 2026 | americanbankingnews.com

Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug

October 1, 2026 | finance.yahoo.com

Shattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa Trial

October 1, 2026 | rttnews.com

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

October 1, 2026 | globenewswire.com

Shattuck Labs (NASDAQ:STTK) Shares Up 11.9% - Time to Buy?

September 30, 2026 | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Stock Rated "Buy" by Sell-Side Brokerages

September 30, 2026 | americanbankingnews.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Buy" from Brokerages

September 25, 2026 | marketbeat.com

Shattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Bank of New York Mellon Corp Buys New Stake in Shattuck Labs, Inc. $STTK

September 10, 2026 | marketbeat.com

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

August 11, 2026 | kalkinemedia.comK

Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026

August 11, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, MDXG, DBVT, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$15.49 +0.29 (+1.91%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.10 (+0.65%)

As of 10/9/2026 06:21 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

DBV Technologies NASDAQ:DBVT

$9.80 +0.25 (+2.62%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.80 +0.00 (+0.05%)

As of 10/9/2026 06:43 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

MiMedx Group NASDAQ:MDXG

$4.67 +0.05 (+1.08%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.66 -0.01 (-0.21%)

As of 10/9/2026 07:30 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Shattuck Labs NASDAQ:STTK

$5.97 +0.31 (+5.48%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.96 -0.01 (-0.18%)

As of 10/9/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, MDXG, DBVT, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, MDXG, DBVT, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, MDXG, DBVT, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, MDXG, DBVT, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

DBV Technologies NASDAQ:DBVT

MiMedx Group NASDAQ:MDXG

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, MDXG, DBVT, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, MDXG, DBVT, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, MDXG, DBVT, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, MDXG, DBVT, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

DBV Technologies NASDAQ:DBVT

MiMedx Group NASDAQ:MDXG

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools